Amicus Therapeutics (FOLD) Stock Price, News & Analysis

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1-year target prices for Amicus Therapeutics' stock. Their FOLD share price targets range from $19.00 to $22.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 88.5% from the stock's current price.
View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts.

Amicus Therapeutics' stock was trading at $14.19 at the start of the year. Since then, FOLD stock has decreased by 25.2% and is now trading at $10.61.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FOLD earnings forecast.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The biopharmaceutical company had revenue of $115.08 million for the quarter, compared to the consensus estimate of $115.11 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative trailing twelve-month return on equity of 119.46%.

ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Guru Index ETF (GURU), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), iShares U.S. Pharmaceuticals ETF (IHE), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.04%), Diversified Trust Co (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Fulton Bank N.A. (0.00%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends.

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.